Alkem Laboratories has announced the incorporation of a new wholly owned subsidiary, Alkem Pharmaceuticals Scientific Office FZ LLC, in Dubai Healthcare City, UAE. The subsidiary will function as a ‘Scientific Office’ to facilitate the manufacturing of products and obtaining product registrations, excluding trading activities.
The authorised share capital for Alkem Pharmaceuticals Scientific Office FZ LLC is set at AED 3,670,000, divided into 3,670 equity shares of AED 1,000 each. The subscribed capital mirrors this structure, also amounting to AED 3,670,000. As a wholly owned subsidiary, Alkem Pharmaceuticals is categorised as a related party to Alkem Laboratories.
Alkem Pharmaceuticals will operate within the pharmaceuticals industry, aligning with Alkem Laboratories’ primary business focus. The subsidiary was officially incorporated on 4th February 2026, although it has not yet reported any turnover figures.
The establishment of this subsidiary is a strategic move by Alkem Laboratories to expand its manufacturing capabilities and streamline the process of obtaining necessary product registrations in the UAE. The initiative does not involve any trading activities, which remains outside the scope of the new entity’s operations.
No governmental or regulatory approvals were required for the acquisition, and the transaction was completed through a cash consideration. Alkem Laboratories has acquired 100% control of the subsidiary by subscribing to all 3,670 equity shares.
It is worth noting that related approvals from the UAE’s Ministry of Health and Prevention have faced delays, possibly due to ongoing regional conflicts.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).